Methylprednisolone Hemisuccinate

Summary

Methylprednisolone Hemisuccinate (CHEMBL1201265) is an approved small molecule; indicated across 3 conditions including relapsing-remitting multiple sclerosis and optic nerve disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 4
• Chemistry: 474.5 Da · C26H34O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201265
Name	Methylprednisolone Hemisuccinate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	16923
Molecular formula	C26H34O8
Molecular weight	474.5
InChIKey	IMBXEJJVJRTNOW-XYMSELFBSA-N

SMILES: C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)COC(=O)CCC(=O)O)O

IUPAC name: 4-[2-[(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-6,10,13-trimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoic acid

Also known as: Methylprednisolone hemisuccinate, Methylprednisolone succinate, SID124896649, METHYLPREDNISOLONE HEMISUCCINATE, methylprednisolone succinate

Parent form; salt/anhydrous children: CHEMBL1201081

Patent coverage: 434 distinct patent families (1,280 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Glucocorticoid receptor.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR3C1	6.17	AC50	670	nM	CHEMBL_ACT_25176332

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
relapsing-remitting multiple sclerosis	2	MONDO:0005314	EFO:0003929
optic nerve disorder	2	MONDO:0002135	MONDO:0002135
multiple sclerosis	1	MONDO:0005301	MONDO:0005301

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE4	1
PHASE2/PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04192656	PHASE4	RECRUITING	The Effect of PAP on ISSHL Comorbided With OSA
NCT05748561	PHASE2/PHASE3	UNKNOWN	Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial.
NCT04979650	PHASE2	COMPLETED	Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis
NCT02048358	PHASE1	TERMINATED	Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).